Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Covestor Ltd

Covestor Ltd increased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 15.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,099 shares of the biopharmaceutical company’s stock after purchasing an additional 288 shares during the quarter. Covestor Ltd’s holdings in Intra-Cellular Therapies were worth $175,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the business. GAMMA Investing LLC grew its position in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 240 shares during the period. Venturi Wealth Management LLC purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth $96,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Intra-Cellular Therapies in the third quarter valued at $97,000. Barlow Wealth Partners Inc. acquired a new position in Intra-Cellular Therapies during the 4th quarter worth $184,000. Finally, R Squared Ltd purchased a new stake in Intra-Cellular Therapies during the 4th quarter worth about $205,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Price Performance

Intra-Cellular Therapies stock opened at $131.87 on Friday. The stock has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The business has a 50 day simple moving average of $130.19 and a 200-day simple moving average of $103.76. Intra-Cellular Therapies, Inc. has a 12 month low of $64.09 and a 12 month high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on ITCI shares. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Canaccord Genuity Group lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their target price for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. StockNews.com started coverage on Intra-Cellular Therapies in a report on Saturday, April 5th. They issued a “hold” rating for the company. Finally, Piper Sandler restated a “neutral” rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Eleven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Intra-Cellular Therapies has a consensus rating of “Hold” and an average price target of $106.23.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.